Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 2Leukemia, Myeloid 2Bronchiolitis Obliterans Syndrome 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
RO6839921 × Clear all
NCT02098967 2018-05-17

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Hoffmann-La Roche

Phase 1 Completed
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms

NCT01677780 2017-07-07

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Hoffmann-La Roche

Phase 1 Completed
11 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡